Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
CASI Pharmaceuticals Inc is a biotechnology business based in the US. CASI Pharmaceuticals shares (CASI) are listed on the NASDAQ and all prices are listed in US Dollars. CASI Pharmaceuticals employs 144 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.06|
|52-week range||$1.08 - $3.90|
|50-day moving average||$1.28|
|200-day moving average||$1.47|
|Wall St. target price||$4.45|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.41|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||-4.50%|
|1 month (2021-09-28)||-13.11%|
|3 months (2021-07-28)||-10.17%|
|6 months (2021-04-28)||-45.08%|
|1 year (2020-10-27)||-49.76%|
|2 years (2019-10-25)||-68.73%|
|3 years (2018-10-26)||2.77|
|5 years (2016-10-27)||1.39|
|Revenue TTM||$22 million|
|Gross profit TTM||$5.6 million|
|Return on assets TTM||-18.41%|
|Return on equity TTM||-50.72%|
|Market capitalisation||$152.4 million|
TTM: trailing 12 months
There are currently 2.5 million CASI Pharmaceuticals shares held short by investors – that's known as CASI Pharmaceuticals's "short interest". This figure is 10.6% down from 2.8 million last month.
There are a few different ways that this level of interest in shorting CASI Pharmaceuticals shares can be evaluated.
CASI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of CASI Pharmaceuticals shares currently shorted divided by the average quantity of CASI Pharmaceuticals shares traded daily (recently around 3.4 million). CASI Pharmaceuticals's SIR currently stands at 0.72. In other words for every 100,000 CASI Pharmaceuticals shares traded daily on the market, roughly 720 shares are currently held short.
However CASI Pharmaceuticals's short interest can also be evaluated against the total number of CASI Pharmaceuticals shares, or, against the total number of tradable CASI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CASI Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CASI Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.022% of the tradable shares (for every 100,000 tradable CASI Pharmaceuticals shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CASI Pharmaceuticals.
Find out more about how you can short CASI Pharmaceuticals stock.
We're not expecting CASI Pharmaceuticals to pay a dividend over the next 12 months.
CASI Pharmaceuticals's shares were split on a 1:11 basis on 30 June 2010. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CASI Pharmaceuticals shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for CASI Pharmaceuticals shares which in turn could have impacted CASI Pharmaceuticals's share price.
Over the last 12 months, CASI Pharmaceuticals's shares have ranged in value from as little as $1.08 up to $3.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CASI Pharmaceuticals's is 0.3238. This would suggest that CASI Pharmaceuticals's shares are less volatile than average (for this exchange).
CASI Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.